At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35 enrolled
Drug / intervention
interoperable Artificial Pancreas System (iAPS) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The International Diabetes Closed Loop (iDCL) Trial: A Randomized Crossover Comparison of Adaptive Model Predictive Control (MPC) Artificial Pancreas Versus Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) in the Outpatient Setting in Type 1 Diabetes (DCLP4)
In Brief
A clinical study evaluating interoperable Artificial Pancreas System (iAPS) and Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) for Type 1 Diabetes. Completed, enrolled 35 participants across 5 sites.
Detailed Summary
The investigators aim to compare the efficacy and safety of an AID system using an adaptive MPC algorithm versus SAP (which may or may not include PLGS; to be referred to as SAP) in people with type 1 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartAug 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedJun 18, 2020
Enrollment StartAug 5, 2020
Primary CompletionMay 10, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.0 years ago
Interventions
interoperable Artificial Pancreas System (iAPS)device
Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.
Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)other
Use of personal pump with study CGM \& glucometer at home for 13 weeks.